Skip to main content
RELMADA THERAPEUTICS, INC. logo

RELMADA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · RLMD ISIN · US75954H1005 LEI · 549300217EASRZ9JSF81 US Professional, scientific and technical activities
Filings indexed 582 across all filing types
Latest filing 2020-08-19 Director's Dealing
Country US United States of America
Listing US RLMD

About RELMADA THERAPEUTICS, INC.

https://www.relmada.com/

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
Director's Dealing 2020
Director's Dealing
2020-08-19 English
Regulatory Filings 2020
Regulatory Filings
2020-08-18 English
REGISTRATION STATEMENT
Regulatory Filings
2020-08-12 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2020
2020-08-12 English
Director's Dealing 2020
Director's Dealing
2020-08-04 English
Director's Dealing 2020
Director's Dealing
2020-07-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.